Reward-seeking behavior and addiction: Cause or cog?

Current Drug Abuse Reviews

Volumn 5, Issue 3, 2012, Pages 178-189

  Arias Carrión, Oscar ^a,b   Salama, Mohamed ^c  

^a HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

Dopamine; Drug addiction; Galanin; Ghrelin; Histamine; Individual variations; Orexin; Reward seeking behavior; Signaling; Synaptic plasticity

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMPHETAMINE; CORTICOTROPIN RELEASING FACTOR; DOPAMINE; DYNORPHIN; GALANIN; GHRELIN; HISTAMINE; NEUROTRANSMITTER; OPIATE; OREXIN; PSYCHOSTIMULANT AGENT;

ARTICLE; BEHAVIOR; BRAIN REGION; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG SELF ADMINISTRATION; ENVIRONMENTAL FACTOR; GENETIC VARIABILITY; HEREDITY; HUMAN; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; PLASTICITY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; REWARD; REWARD-SEEKING BEHAVIOR; SOCIAL BEHAVIOR; SUBSTANTIA NIGRA;

ANIMALS; BEHAVIOR, ADDICTIVE; CUES; DOPAMINE; GENETIC VARIATION; HUMANS; NEUROTRANSMITTER AGENTS; REWARD; SOCIAL BEHAVIOR; SUBSTANCE-RELATED DISORDERS;

EID: 84869132149     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711205030178     Document Type: Article

References (175)

1. Arias-Carrion O, Stamelou M, Murillo-Rodriguez E, Menendez-Gonzalez M, Poppel E. Dopaminergic reward system: a short integrative review. Int Arch Med 2010; 3: 24.
2. Pagnoni G, Zink CF, Montague PR, Berns GS. Activity in human ventral striatum locked to errors of reward prediction. Nat Neurosci 2002; 5: 97-8.
3. Shizgal P. Neural basis of utility estimation. Curr Opin Neurobiol 1997; 7: 198-208.
4. Childress AR, Ehrman RN, Wang Z, et al. Prelude to passion: limbic activation by "unseen" drug and sexual cues. PLoS One 2008; 3: e1506.
5. Carelli RM. Nucleus accumbens cell firing during goal-directed behaviors for cocaine vs. 'natural' reinforcement. Physiol Behav 2002; 76: 379-87.
6. Robinson DL, Carelli RM. Distinct subsets of nucleus accumbens neurons encode operant responding for ethanol versus water. Eur J Neurosci 2008; 28: 1887-94.
7. Olsen CM. Natural rewards, neuroplasticity, and non-drug addictions. Neuropharmacology 2011; 61: 1109-22.
8. Anselme P. The effect of exposure to drugs on the processing of natural rewards. Neurosci Biobehav Rev 2009; 33: 314-35.
9. Kalivas, P.W., Volkow, N.D. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162: 1403-13.
10. Ghitza UE, Zhai H, Wu P, et al. Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci Biobehav Rev 2010; 35: 157-71.
11. Wanat MJ, Willuhn I, Clark JJ, Phillips PE. Phasic dopamine release in appetitive behaviors and drug addiction. Curr Drug Abuse Rev 2009; 2: 195-213.
12. Frascella J, Potenza MN, Brown LL, Childress AR. Shared brain vulnerabilities open the way for nonsubstance addictions: carving addiction at a new joint? Ann N Y Acad Sci 2010; 1187: 294-315.
13. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35: 217-38.
14. Pierce RC, Vanderschuren LJ. Kicking the habit: the neural basis of ingrained behaviors in cocaine addiction. Neurosci Biobehav Rev 2010; 35: 212-9.
15. Russo SJ, Dietz DM, Dumitriu D, et al. The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci 2010; 33: 267-76.
16. Mameli M, Bellone C, Brown MT, Luscher C. Cocaine inverts rules for synaptic plasticity of glutamate transmission in the ventral tegmental area. Nat Neurosci 2011; 14: 414-6.
17. Robinson TE, Berridge KC. Review. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3137-46.
18. Avena NM, Hoebel BG. A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine. Neuroscience 2003; 122: 17-20.
19. Koob GF, Le Moal M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3113-23.
20. Solomon RL, Corbit JD. An opponent-process theory of motivation. I. Temporal dynamics of affect. Psychol Rev 1974; 81: 119-45.
21. Solomon RL. The opponent-process theory of acquired motivation: the costs of pleasure and the benefits of pain. Am Psychol 1980; 35: 691-712.
22. George O, Le Moal M, Koob GF. Allostasis and addiction: Role of the dopamine and corticotropin-releasing factor systems. Physiol Behav 2012; 106: 58-64.
23. Porrino LJ, Daunais JB, Smith HR, Nader MA. The expanding effects of cocaine: studies in a nonhuman primate model of cocaine self-administration. Neurosci Biobehav Rev 2004; 27: 813-20.
24. Balleine BW, Dickinson A. Goal-directed instrumental action: contingency and incentive learning and their cortical substrates. Neuropharmacology 1998; 37: 407-19.
25. Alcaro A, Huber R, Panksepp J. Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res Rev 2007; 56: 283-321.
26. Ikemoto S, Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev 1999; 31: 6-41.
27. Wise RA. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res 2008; 14: 169-83.
28. Ikemoto S. Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory. Neurosci Biobehav Rev 2010; 35: 129-50.
29. Alcaro, A., Panksepp, J. The SEEKING mind: primal neuroaffective substrates for appetitive incentive states and their pathological dynamics in addictions and depression. Neurosci Biobehav Rev 2011; 35: 1805-20.
30. Koob GF. Dynamics of neuronal circuits in addiction: reward, antireward, and emotional memory. Pharmacopsychiatry 2009; 42 Suppl 1: S32-41.
31. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998; 28: 309-69.
32. Arias-Carrion O, Poppel E. Dopamine, learning, and rewardseeking behavior. Acta Neurobiol Exp (Wars) 2007; 6: 481-8.
33. Phillips AG, Vacca G, Ahn S. A top-down perspective on dopamine, motivation and memory. Pharmacol Biochem Behav 2008; 90: 236-49.
34. Montague PR, Dayan P, Sejnowski TJ. A framework for mesencephalic dopamine systems based on predictive Hebbian learning. J Neurosci 1996; 16: 1936-47.
35. Montague, P.R. Integrating information at single synaptic connections. Proc Natl Acad Sci U S A 1995; 92: 2424-5.
36. Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007; 30: 194-202.
37. Smith Y, Villalba R. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Mov Disord 2008; 23 Suppl 3: S534-47.
38. Barbeau A. High-level levodopa therapy in Parkinson's disease: five years later. Trans Am Neurol Assoc 1974; 99: 160-3.
39. Yim CY, Mogenson GJ. Electrophysiological studies of neurons in the ventral tegmental area of Tsai. Brain Res 1980; 181: 301-13.
40. D'Ardenne K, McClure SM, Nystrom LE, Cohen JD. BOLD responses reflecting dopaminergic signals in the human ventral tegmental area. Science 2008; 319: 1264-7.
41. Wise RA. Forebrain substrates of reward and motivation. J Comp Neurol 2005; 493: 115-21.
42. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci 2004; 5: 483-94.
43. Weidong L, Shen C, Jankovic J. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist 2009; 15: 28-35.
44. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 2002; 53: 590-605.
45. Zhou FM, Wilson C, Dani JA. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 2003; 9: 23-36.
46. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998; 78: 189-225.
47. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000; 24: 125-32.
48. Saji H, Iida Y, Kawashima H, et al. In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. Anal Sci 2003; 19: 67-71.
49. Jaber M, Robinson SW, Missale C, Caron MG. Dopamine receptors and brain function. Neuropharmacology 1996; 35: 1503-19.
50. Verhoeff NP. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology (Berl) 1999; 147: 217-49.
51. Piccini P. Neurodegenerative movement disorders: the contribution of functional imaging. Curr Opin Neurol 2004; 17: 459-66.
52. Greengard P. The neurobiology of dopamine signaling. Biosci Rep 2001; 21: 247-69.
53. Sesack SR, Carr DB, Omelchenko N, Pinto A. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann N Y Acad Sci 2003; 1003: 36-52.
54. Lapish CC, Kroener S, Durstewitz D, Lavin A, Seamans JK. The ability of the mesocortical dopamine system to operate in distinct temporal modes. Psychopharmacology (Berl) 2007; 191: 609-25.
55. Venton BJ, Zhang H, Garris PA, et al. Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. J Neurochem 2003; 87: 1284-95.
56. O'Donnell P. Dopamine gating of forebrain neural ensembles. Eur J Neurosci 2003; 17: 429-35.
57. Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 2007; 30: 228-35.
58. Gonon F. Prolonged and extrasynaptic excitatory action of dopamine mediated by D1 receptors in the rat striatum in vivo. J Neurosci 1997; 17: 5972-8.
59. Schultz W. Getting formal with dopamine and reward. Neuron 2002; 36: 241-63.
60. Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci 2007; 30: 259-88.
61. Schultz W. Behavioral dopamine signals. Trends Neurosci 2007; 30: 203-10.
62. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988; 85: 5274-8.
63. Olive MF, Koenig HN, Nannini MA, Hodge CW. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J Neurosci 2001; 21: RC184.
64. Lin Z, Uhl GR. Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Mol Pharmacol 2002; 61: 885-91.
65. Zahniser NR, Sorkin A. Trafficking of dopamine transporters in psychostimulant actions. Semin Cell Dev Biol 2009; 20: 411-7.
66. Kahlig KM, Lute BJ, Wei Y, et al. Regulation of dopamine transporter trafficking by intracellular amphetamine. Mol Pharmacol 2006; 170: 542-8.
67. Zhu J, Reith ME. Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol Disord Drug Targets 2008; 7: 393-409.
68. Kienast T, Heinz A. Dopamine and the diseased brain. CNS Neurol Disord Drug Targets 2006; 5: 109-31.
69. Kumar S, Porcu P, Werner DF, et al. The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of progress. Psychopharmacology (Berl) 2009; 205: 529-64.
70. Mereu G, Gessa GL. Low doses of ethanol inhibit the firing of neurons in the substantia nigra, pars reticulata: a GABAergic effect? Brain Res 1985; 360: 325-30.
71. Windels F, Kiyatkin EA. GABAergic mechanisms in regulating the activity state of substantia nigra pars reticulata neurons. Neuroscience 2006; 140: 1289-99.
72. Robinson DL, Howard EC, McConnell S, Gonzales RA, Wightman RM. Disparity between tonic and phasic ethanol-induced dopamine increases in the nucleus accumbens of rats. Alcohol Clin Exp Res 2009; 33: 1187-96.
73. Howard EC, Schier CJ, Wetzel JS, Gonzales RA. The Dopamine response in the nucleus accumbens core-shell border differs from that in the core and shell during operant ethanol self-administration. Alcohol Clin Exp Res 2009; 33: 1355-65.
74. Haile CN, Kosten TA, Kosten TR. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 2008; 34: 355-81.
75. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov 2002; 1: 710-26.
76. Churchill L, Klitenick MA, Kalivas PW. Dopamine depletion reorganizes projections from the nucleus accumbens and ventral pallidum that mediate opioid-induced motor activity. J Neurosci 1998; 18: 8074-85.
77. Sorge RE, Clarke PB. Rats self-administer intravenous nicotine delivered in a novel smoking-relevant procedure: effects of dopamine antagonists. J Pharmacol Exp Ther 2009; 330: 633-40.
78. Le Foll B, Gallo A, Le Strat Y, Lu L, Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol 2009; 20: 1-17.
79. Rothman RB, Gendron T, Hitzig P. Hypothesis that mesolimbic dopamine (DA) plays a key role in mediating the reinforcing effects of drugs of abuse as well as the rewarding effects of ingestive behaviors. J Subst Abuse Treat 1994; 11: 273-5.
80. Brami-Cherrier K, Roze E, Girault JA, Betuing S, Caboche J. Role of the ERK/MSK1 signalling pathway in chromatin remodelling and brain responses to drugs of abuse. J Neurochem 2009; 108: 1323-35.
81. Zhang D, Zhang H, Jin GZ, Zhang K, Zhen X. Single dose of morphine produced a prolonged effect on dopamine neuron activities. Mol Pain 2008; 4: 57.
82. Berridge KC, Kringelbach ML. Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology (Berl) 2008; 199: 457-80.
83. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007; 191: 391-431.
84. Rocha BA, Odom LA, Barron BA, et al. Differential responsiveness to cocaine in C57BL/6J and DBA/2J mice. Psychopharmacology (Berl) 1998; 138: 82-8.
85. McNamara RK, Levant B, Taylor B, et al. C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice. Neuroscience 2006; 143: 141-53.
86. Belej T, Manji D, Sioutis S, Barros HM, Nobrega JN. Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre-vs. post-withdrawal effects. Brain Res 1996; 736: 287-96.
87. Johnson, B.A. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs 2004; 18: 1105-18.
88. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008; 75: 34-56.
89. Feil J, Sheppard D, Fitzgerald PB, et al. Addiction, compulsive drug seeking, and the role of frontostriatal mechanisms in regulating inhibitory control. Neurosci Biobehav Rev 2010; 35: 248-75.
90. Kelley AE. Functional specificity of ventral striatal compartments in appetitive behaviors. Ann N Y Acad Sci 1999; 877: 71-90.
91. Aragona BJ, Cleaveland NA, Stuber GD, et al. Preferential enhancement of dopamine transmission within the nucleus accumbens shell by cocaine is attributable to a direct increase in phasic dopamine release events. J Neurosci 2008; 28: 8821-31.
92. Ikemoto S, Qin M, Liu ZH. The functional divide for primary reinforcement of D-amphetamine lies between the medial and lateral ventral striatum: is the division of the accumbens core, shell, and olfactory tubercle valid? J Neurosci 2005; 25: 5061-5.
93. Reynolds SM, Berridge KC. Positive and negative motivation in nucleus accumbens shell: bivalent rostrocaudal gradients for GABA-elicited eating, taste "liking"/"disliking" reactions, place preference/avoidance, and fear. J Neurosci 2002; 22: 7308-20.
94. Wheeler RA, Aragona BJ, Fuhrmann KA, et al. Cocaine cues drive opposing context-dependent shifts in reward processing and emotional state. Biol Psychiatry 2011; 69: 1067-74.
95. Land BB, Bruchas MR, Lemos JC, et al. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 2008; 28: 407-14.
96. Hjelmstad GO, Fields HL. Kappa opioid receptor activation in the nucleus accumbens inhibits glutamate and GABA release through different mechanisms. J Neurophysiol 2003; 89: 2389-95.
97. Frankel PS, Alburges ME, Bush L, Hanson GR, Kish SJ. Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 2008; 55: 41-6.
98. Hooks MS, Jones GH, Smith AD, Neill DB, Justice JB, Jr. Individual differences in locomotor activity and sensitization. Pharmacol Biochem Behav 1991; 38: 467-70.
99. Lajtha A, Sershen H. Heterogeneity of reward mechanisms. Neurochem Res 2010; 35: 851-67.
100. Piazza PV, Rouge-Pont F, Deminiere JM, et al. Dopaminergic activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration. Brain Res 1991; 567: 169-74.
101. Hooks MS, Juncos JL, Justice JB, Jr, et al. Individual locomotor response to novelty predicts selective alterations in D1 and D2 receptors and mRNAs. J Neurosci 1994; 14: 6144-52.
102. Piazza PV, Deroche-Gamonent V, Rouge-Pont F, Le Moal M. Vertical shifts in self-administration dose-response functions predict a drug-vulnerable phenotype predisposed to addiction. J Neurosci 2000; 20: 4226-32.
103. Flagel SB, Akil H, Robinson TE. Individual differences in the attribution of incentive salience to reward-related cues: Implications for addiction. Neuropharmacology 2009; 56 Suppl 1: 139-48.
104. Volkow ND, Wang GJ, Fowler JS, et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 1999; 156: 1440-3.
105. Leyton M, Boileau I, Benkelfat C, et al. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 2002; 27: 1027-35.
106. Yacubian J, Buchel C. The genetic basis of individual differences in reward processing and the link to addictive behavior and social cognition. Neuroscience 2009; 164: 55-71.
107. Skuse D, Lawrence K, Tang J. Measuring social-cognitive functions in children with somatotropic axis dysfunction. Horm Res 2005; 64 (Suppl 3): 73-82.
108. Johnson MH, Griffin R, Csibra G, et al. The emergence of the social brain network: evidence from typical and atypical development. Dev Psychopathol 2005; 17: 599-619.
109. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24: 97-129.
110. Carroll ME, Lac ST. Autoshaping i.v. cocaine self-administration in rats: effects of nondrug alternative reinforcers on acquisition. Psychopharmacology (Berl) 1993; 110: 5-12.
111. Carroll ME, Rodefer JS, Rawleigh JM. Concurrent selfadministration of ethanol and an alternative nondrug reinforcer in monkeys: effects of income (session length) on demand for drug. Psychopharmacology (Berl) 1995; 120: 1-9.
112. Higgins ST, Bickel WK, Hughes JR. Influence of an alternative reinforcer on human cocaine self-administration. Life Sci 1994; 55: 179-87.
113. Machado S, Paes F, Velasques B, et al. Is rTMS an effective therapeutic strategy that can be used to treat anxiety disorders? Neuropharmacology 2012; 62: 125-34.
114. Fergusson DM, Horwood LJ, Lynskey MT, Madden PA. Early reactions to cannabis predict later dependence. Arch Gen Psychiatry 2003; 60: 1033-9.
115. Fride E, Weinstock M. Alterations in behavioral and striatal dopamine asymmetries induced by prenatal stress. Pharmacol Biochem Behav 1989; 32: 425-30.
116. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015.
117. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-74.
118. Arias-Carrion O, Murillo-Rodriguez E, Xu M, et al. Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 2004; 27: 1465-70.
119. Arias-Carrion O, Murillo-Rodriguez E. Cell transplantation: a future therapy for narcolepsy? CNS Neurol Disord Drug Targets 2009; 8: 309-14.
120. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 2007; 8: 171-81.
121. Date Y, Ueta Y, Yamashita H, et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci U S A 1999; 96: 748-53.
122. van den Pol AN. Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. J Neurosci 1999; 19: 3171-82.
123. Arias-Carrion O, Drucker-Colin R, Murillo-Rodriguez E. Survival rates through time of hypocretin grafted neurons within their projection site. Neurosci Lett 2006; 404: 93-7.
124. Nakamura T, Uramura K, Nambu T, et al. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res 2000; 873: 181-7.
125. Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005; 437: 556-9.
126. Boutrel B, Kenny PJ, Specio SE, et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci U S A 2005; 102: 19168-73.
127. Narita M, Nagumo Y, Hashimoto S, et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci 2006; 26: 398-405.
128. Narita M, Nagumo Y, Miyatake M, et al. Implication of protein kinase C in the orexin-induced elevation of extracellular dopamine levels and its rewarding effect. Eur J Neurosci 2007; 25: 1537-45.
129. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 2006; 49: 589-601.
130. de Lecea L, Jones BE, Boutrel B, et al. Addiction and arousal: alternative roles of hypothalamic peptides. J Neurosci 2006; 26: 10372-5.
131. Georgescu D, Zachariou V, Barrot M, et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 2003; 23: 3106-11.
132. Guilleminault C, Carskadon M, Dement WC. On the treatment of rapid eye movement narcolepsy. Arch Neurol 1974; 30: 90-3.
133. Cason AM, Smith RJ, Tahsili-Fahadan P, et al. Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity. Physiol Behav 2010; 100: 419-28.
134. Smith RJ, Tahsili-Fahadan P, Aston-Jones G. Orexin/hypocretin is necessary for context-driven cocaine-seeking. Neuropharmacology 2010; 58: 179-84.
135. Smith RJ, See RE, Aston-Jones G. Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. Eur J Neurosci 2009; 30: 493-503.
136. Richards JK, Simms JA, Steensland P, et al. Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. Psychopharmacology (Berl) 2008; 199: 109-17.
137. Honigberg SM, Lee RH. Snf1 kinase connects nutritional pathways controlling meiosis in Saccharomyces cerevisiae. Mol Cell Biol 1998; 18: 4548-55.
138. Harris GC, Aston-Jones G. Arousal and reward: a dichotomy in orexin function. Trends Neurosci 2006; 29: 571-7.
139. Estabrooke IV, McCarthy MT, Ko E, et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci 2001; 21: 1656-62.
140. Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 2002; 22: 6742-6.
141. Xie X, Wisor JP, Hara J, et al. Hypocretin/orexin and nociceptin/orphanin FQ coordinately regulate analgesia in a mouse model of stress-induced analgesia. J Clin Invest 2008; 118: 2471-81.
142. Martin-Fardon R, Zorrilla EP, Ciccocioppo R, Weiss F. Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: Focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin. Brain Res 2010; 1314: 145-61.
143. Lester DB, Rogers TD, Blaha CD. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010; 16: 137-62.
144. Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/-mice and patients. Neurobiol Dis 2008; 30: 74-83.
145. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev 2008; 88: 1183-241.
146. Pillot C, Heron A, Cochois V, et al. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 2002; 114: 173-93.
147. Ogawa S, Yanai K, Watanabe T, et al. Histamine responses of large neostriatal interneurons in histamine H1 and H2 receptor knock-out mice. Brain Res Bull 2009; 78: 189-94.
148. Brabant C, Alleva L, Quertemont E, Tirelli E. Involvement of the brain histaminergic system in addiction and addiction-related behaviors: a comprehensive review with emphasis on the potential therapeutic use of histaminergic compounds in drug dependence. Prog Neurobiol 2010; 92: 421-41.
149. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun 2001; 280: 132-8.
150. Holst B, Schwartz TW. Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends Pharmacol Sci 2004; 25: 113-7.
151. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984; 114: 1537-45.
152. Abizaid A, Liu ZW, Andrews ZB, et al. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest 2006; 116: 3229-39.
153. Dickson SL, Hrabovszky E, Hansson C, et al. Blockade of central nicotine acetylcholine receptor signaling attenuate ghrelin-induced food intake in rodents. Neuroscience 2010; 171: 1180-6.
154. Jerlhag E, Landgren S, Egecioglu E, Dickson SL, Engel JA. The alcohol-induced locomotor stimulation and accumbal dopamine release is suppressed in ghrelin knockout mice. Alcohol 2011; 45: 341-7.
155. Jiang H, Betancourt L, Smith RG. Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Mol Endocrinol 2006; 20: 1772-85.
156. Jerlhag E, Egecioglu E, Landgren S, et al. Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci U S A 2009; 106: 11318-23.
157. Egecioglu E, Jerlhag E, Salome N, et al. Ghrelin increases intake of rewarding food in rodents. Addict Biol 2010; 15: 304-11.
158. Tatemoto K, Rokaeus A, Jornvall H, McDonald TJ, Mutt V. Galanin-a novel biologically active peptide from porcine intestine. FEBS Lett 1983; 164: 124-8.
159. Xu XJ, Hokfelt T, Wiesenfeld-Hallin Z. Galanin and spinal pain mechanisms: where do we stand in 2008? Cell Mol Life Sci 2008; 65: 1813-9.
160. Kolakowski LF, Jr, O'Neill GP, Howard AD, et al. Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. J Neurochem 1998; 71: 2239-51.
161. Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 2007; 115: 177-207.
162. Hawes JJ, Narasimhaiah R, Picciotto MR. Galanin and galanin-like peptide modulate neurite outgrowth via protein kinase C-mediated activation of extracellular signal-related kinase. Eur J Neurosci 2006; 23: 2937-46.
163. Tsuda K, Tsuda S, Nishio I, Masuyama Y, Goldstein M. Effects of galanin on dopamine release in the central nervous system of normotensive and spontaneously hypertensive rats. Am J Hypertens 1998; 11: 1475-9.
164. Ericson E, Ahlenius S. Suggestive evidence for inhibitory effects of galanin on mesolimbic dopaminergic neurotransmission. Brain Res 1999; 822: 200-9.
165. Weiss JM, Boss-Williams KA, Moore JP, et al. Testing the hypothesis that locus coeruleus hyperactivity produces depressionrelated changes via galanin. Neuropeptides 2005; 39: 281-7.
166. Holmes A, Kinney JW, Wrenn CC, et al. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Neuropsychopharmacology 2003; 28: 1031-44.
167. Zachariou V, Parikh K, Picciotto MR. Centrally administered galanin blocks morphine place preference in the mouse. Brain Res 1999; 831: 33-42.
168. Hawes JJ, Brunzell DH, Narasimhaiah R, et al. Galanin protects against behavioral and neurochemical correlates of opiate reward. Neuropsychopharmacology 2008; 33: 1864-73.
169. Befort K, Filliol D, Ghate A, et al. Mu-opioid receptor activation induces transcriptional plasticity in the central extended amygdala. Eur J Neurosci 2008; 27: 2973-84.
170. Zachariou V, Thome J, Parikh K, Picciotto MR. Upregulation of galanin binding sites and GalR1 mRNA levels in the mouse locus coeruleus following chronic morphine treatments and precipitated morphine withdrawal. Neuropsychopharmacology 2000; 23: 127-37.
171. Levran O, Londono D, O'Hara K, et al. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav 2008; 7: 720-9.
172. Narasimhaiah R, Kamens HM, Picciotto MR. Effects of galanin on cocaine-mediated conditioned place preference and ERK signaling in mice. Psychopharmacology (Berl) 2009; 204: 95-102.
173. Kuteeva E, Hokfelt T, Ogren SO. Behavioural characterisation of young adult transgenic mice overexpressing galanin under the PDGF-B promoter. Regul Pept 2005; 125: 67-78.
174. Schneider ER, Rada P, Darby RD, Leibowitz SF, Hoebel BG. Orexigenic peptides and alcohol intake: differential effects of orexin, galanin, and ghrelin. Alcohol Clin Exp Res 2007; 31: 1858-65.
175. Picciotto MR, Brabant C, Einstein EB, Kamens HM, Neugebauer NM. Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction-and stress-related behaviors. Brain Res 2010; 1314: 206-18.